How LSD and DMT compare — duration, legal status, religious-exemption access, and how far each drug program has reached in clinical trials.
Comparing LSD vs DMT comes down to three things: how long the experience lasts, where either drug has any real legal access today, and how far each one's clinical drug program has actually progressed. Both are classic psychedelics that share a main mechanism, but the practical differences are large. This guide compares them side by side.
DMT is the far shorter, far more intense experience, and it is the only one of the two with any real legal access in the US today, through Colorado's decriminalization law or a recognized ayahuasca church. LSD lasts most of a day, has no legal access path outside a clinical trial anywhere in the country, but its pharmaceutical program (DT120) has moved further through FDA trials than any DMT program has. Neither drug is approved or legal for general use.
| Factor | LSD | DMT |
|---|---|---|
| Legal status (US) | Schedule I. No state has decriminalized it and no religious exemption exists. | Schedule I federally. Colorado decriminalized personal possession (Prop 122); 4 religious organizations hold DEA exemptions for ayahuasca. |
| Typical duration | ~8–11 hours. | ~5–20 minutes smoked/vaporized; ~4–6 hours as ayahuasca (oral, with a plant MAOI). |
| Primary mechanism | Partial agonist at the 5-HT2A serotonin receptor; also touches dopamine receptors. | Agonist at the 5-HT2A serotonin receptor. |
| Lead drug candidate | DT120 (Definium Therapeutics), an oral tablet form of LSD tartrate. | HLP004 (Helus Pharma), a follow-on molecule from the discontinued SPL026 IV-DMT program. |
| Clinical trial stage (2026) | Phase 3. Voyage (anxiety) and Emerge (depression) both reported positive topline results by August 2026; Panorama (confirmatory anxiety trial) still pending. | Phase 2, for generalized anxiety disorder. The earlier SPL026 depression program met its Phase 2a endpoint but was not advanced further. |
| Real-world legal access today | None. Clinical trial enrollment is the only legal route in the US. | Ayahuasca ceremonies through a recognized US religious exemption, or retreat centers abroad in countries such as Peru, Costa Rica, and Ecuador. |
| Analogue-law risk | 1P-LSD and 1S-LSD can trigger Federal Analogue Act prosecution as LSD-substantially-similar compounds. | 4-AcO-DMT can trigger Federal Analogue Act prosecution as a DMT-substantially-similar compound. |
LSD and DMT both act mainly on the 5-HT2A serotonin receptor, the shared target that puts them, along with psilocybin, in the "classic psychedelic" category. LSD is a partial agonist there and binds unusually tightly, which is part of why its effects last so long. DMT is a fuller agonist at the same receptor but is cleared from the body within minutes when smoked, which is why the two drugs feel so different in practice despite sharing a core mechanism.
Read our full LSD guide and DMT guide for the pharmacology and research history of each in more depth.
Duration is the biggest practical difference between these two drugs. An LSD session runs 8 to 11 hours: onset within 30 to 90 minutes, a plateau over several hours, and a slow return to baseline. Smoked or vaporized DMT is the opposite extreme: onset in seconds, a peak at 2 to 5 minutes, and a full return to baseline by 15 to 20 minutes.
DMT taken orally as ayahuasca changes the picture. A plant-based MAOI in the brew keeps DMT active in the body for 4 to 6 hours instead of minutes, with a slower onset and a more ceremony-like arc than smoked DMT. Even so, an ayahuasca session is still shorter than a typical LSD dose. For someone weighing a supported session, LSD demands most of a day; DMT, in either form, does not.
LSD's modern drug-development program is further along than any DMT program. Definium Therapeutics (formerly MindMed) developed DT120, an orally disintegrating tablet form of LSD tartrate that holds FDA Breakthrough Therapy Designation for generalized anxiety disorder. By August 2026, both of its Phase 3 trials that had read out, Voyage (anxiety) and Emerge (depression), reported positive topline results. Panorama, the confirmatory anxiety trial, is still pending.
DMT's path has been rockier. Small Pharma's SPL026, an intravenous DMT formulation, met its Phase 2a endpoint for major depressive disorder: a statistically significant reduction in depression scores versus placebo. After Cybin acquired Small Pharma and rebranded to Helus Pharma in early 2026, the company chose not to advance the IV-DMT depression formulation further. Its current lead DMT-derived candidate, HLP004, is in Phase 2 for generalized anxiety disorder, with data expected later in 2026, well behind DT120's Phase 3 stage.
Both LSD and DMT are Schedule I at the federal level, meaning no accepted medical use and no prescription path today. The real gap between them is what happens below the federal line. LSD has no state-level decriminalization anywhere in the US and no religious exemption covers it. DMT has both: Colorado's Prop 122 decriminalized personal possession for adults 21 and older, and four US religious organizations (the UDV, Santo Daime, Iowaska Church of Healing, and the Church of Gaia) hold confirmed federal DEA exemptions to use DMT-containing ayahuasca.
That gap carries through internationally. Ayahuasca retreat centers operate openly in countries such as Peru, Costa Rica, and Ecuador, giving DMT (in that form) a real, if unregulated by US standards, access route abroad. LSD has no comparable retreat model anywhere. For the country-by-country and state-by-state detail behind each drug, see where DMT is legal and the legal status by state tool.
Decriminalization is not legalization. Even in Colorado, selling or distributing DMT remains a felony; only personal possession was decriminalized. And a religious exemption protects the specific organizations the DEA has recognized, not ayahuasca use in general.
Consider DMT (as ayahuasca) if you are weighing a real-world legal access route today, whether through a recognized US religious exemption or a retreat abroad, and you can commit to its demanding, MAOI-dependent brew and ceremony structure.
Consider LSD if you are following anxiety or depression drug development specifically. DT120's Phase 3 results put it closer to a future FDA-approved medicine than any DMT candidate, but that route is only open through clinical trial enrollment right now, not general access.
For the closely related question of how LSD compares to a more clinically advanced classic psychedelic, see our LSD vs psilocybin guide, or take our which psychedelic quiz for a personalized starting point. To search open studies for either drug, use our clinical trial finder.
Neither is legal for general use, but DMT has one narrow opening LSD does not. Colorado decriminalized personal possession of DMT under Prop 122 (2022), and four US religious organizations (UDV, Santo Daime, Iowaska Church of Healing, and the Church of Gaia) hold federal DEA exemptions to use DMT-containing ayahuasca. LSD has no state-level decriminalization and no religious exemption anywhere in the US. Both remain Schedule I federally, and sale or distribution of either is a felony everywhere, including Colorado.
DMT's smoked experience hits harder and faster: full effects arrive within seconds and peak by the 2 to 5 minute mark, often described as a complete break from ordinary reality. LSD builds more gradually over 30 to 90 minutes and stays at a sustained, usually more navigable, intensity for hours. Which one feels 'stronger' is subjective and depends heavily on dose, but DMT's onset is unmatched among classic psychedelics.
LSD lasts far longer in its usual form. A therapeutic or recreational LSD dose runs 8 to 11 hours. Smoked or vaporized DMT returns to baseline within 15 to 20 minutes. DMT taken orally as ayahuasca, where a plant MAOI keeps it active in the body, lasts 4 to 6 hours, which is still shorter than a typical LSD session.
There is no controlled clinical research on combining LSD and DMT, and this guide does not provide dosing advice for mixing them. Both are potent serotonergic psychedelics acting on the same 5-HT2A receptor, so combining them is likely to intensify and extend the effects of each in an unpredictable way. Anyone considering this should talk to a licensed clinician about the risks first, including for anyone with a personal or family history of psychosis.
LSD is further along. Definium Therapeutics' DT120 (the compound originally developed by MindMed as MM120) holds FDA Breakthrough Therapy Designation and posted positive Phase 3 topline results in both the Voyage trial (anxiety) and the Emerge trial (depression) by August 2026, with the confirmatory Panorama trial still pending. DMT's furthest-along depression candidate, Small Pharma's SPL026, met its Phase 2a endpoint but was not advanced further after Cybin's acquisition; the follow-on molecule, Helus Pharma's HLP004, remains in Phase 2 for generalized anxiety disorder.
Get psychedelic research & policy updates
New trials, FDA decisions, and legal changes for psychedelic — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.